Kempharm isn't just another biotech chasing a blockbuster drug. With $28.4M in revenue and a laser focus on rare diseases, they're proving that a 'rare approach' to therapeutics isn't just a tagline—it's a survival strategy in a crowded market.

"They aren't just developing drugs; they're weaving regulatory narratives that force the system to see unmet needs."

• Controlled substance expertise: 'Is Azstarys a controlled medication?' gets 390 monthly searches—proving they're tackling complex regulatory territory competitors avoid
• Strategic rebranding: Kempharm is now Zevra Therapeutics, signaling a broader rare disease vision beyond stimulants
• Data-first narrative: Their approach 'follows the data' to build regulatory arguments that put patients first—not just science

The tech stack reveals their digital strategy: Tailwind CSS and Bootstrap suggest a focus on clean, functional web presence rather than flashy biotech marketing. With only 34% organic traffic, they're not playing the SEO game—they're playing the regulatory and clinical data game. The 80% traffic from 'undefined' countries hints at either privacy-focused analytics or a strategic international footprint that doesn't prioritize US digital marketing.